{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:29:45Z","timestamp":1777930185085,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Die 31P-Magnetresonanzspektroskopie (MRS) ist ein neues Verfahren zur nichtinvasiven In-vivo-Untersuchung des Energie- und Phospholipidstoffwechsels von Geweben. Wegen der hohen technischen Anforderungen hat das Verfahren bisher noch keinen Eingang in die klinische Routine gefunden. Anhand von Einzelbeispielen werden die M\u00f6glichkeiten und Grenzen der 31P-MRS f\u00fcr die Tumortherapieverlaufskontrolle aufgezeigt. Die neuesten Ergebnisse deuten darauf hin, da\u00df mit der 31 P-MRS Effekte im Tumorstoffwechsel nach Chemotherapie innerhalb der ersten 2 Tage nachweisbar sind und damit fr\u00fcher als mit konventionellen Verfahren eine m\u00f6gliche Tumorantwort festgestellt werden kann. Es bedarf jedoch noch weiterer, ausgedehnter klinischer Studien und technischer Entwicklungen, bevor die 31P-MRS f\u00fcr die klinische Routine zur Verf\u00fcgung steht.<\/jats:p>","DOI":"10.1159\/000216686","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T10:05:34Z","timestamp":1240999534000},"page":"46-50","source":"Crossref","is-referenced-by-count":1,"title":["Nicht-invasive Tumortherapieverlaufskontrolle nach Chemotherapie mit Hilfe der\n                    <sup>31<\/sup>\n                    P-MR-Spektroskopie an einem Ganzk\u00f6rpertomographen"],"prefix":"10.1159","author":[{"given":"W.","family":"Semmler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bachert-Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"G\u00fcckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gademann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-J.","family":"Zabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"van Kaick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,27]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000216686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:06:22Z","timestamp":1777680382000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000216686","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,27]]}}}